Meridian Life Science manufactured the influenza A challenge stock according to appropriate current Good Manufacturing Practices parts 21 CFR Parts 210 and 211 for use in Phase 1 human clinical trials to the desired specifications and under aggressive timelines; allowing Immune Targeting Systems to meet critical clinical development timelines.
http://eon.businesswire.com/news/eon/20130730005021/en/Meridian-Life-Science%C2%AE-Successfully-Manufactures-Influenza-Challenge
http://eon.businesswire.com/news/eon/20130730005021/en/Meridian-Life-Science%C2%AE-Successfully-Manufactures-Influenza-Challenge
No comments:
Post a Comment